New pharmacological approaches to the cholinergic system: An overview on muscarinic receptor ligands and cholinesterase inhibitors

Recent Patents on CNS Drug Discovery

Volumn 8, Issue 2, 2013, Pages 1-19

  Greig, Nigel H ^a   Reale, Marcella ^b   Tata, Ada M ^c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acetylcholinesterase; Butirylcholinesterase; Muscarinic receptors; Neurological diseases; Nociception; Tumors

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ACETYLCHOLINESTERASE; ALVAMELINE; BENZATROPINE MESILATE; CEVIMELINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DARIFENACIN; DONEPEZIL; FESOTERODINE; GALANTAMINE; GALLAMINE; IPROTROPIUM; LADOSTIGIL; MEMANTINE; METHOCTRAMINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXITROPIUM BROMIDE; PHYSOSTIGMINE SALICYLATE; PIRENZEPINE; RIVASTIGMINE; SOLIFENACIN; TACRINE; TIOTROPIUM BROMIDE; TOLTERODINE; TROPICAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDACLIDINE; XANOMELINE;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANGIOGENESIS; ASTROCYTOMA; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHOLINERGIC SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITION; COLON CANCER; DIARRHEA; DRUG BINDING SITE; DRUG STRUCTURE; DRY EYE; DYSPEPSIA; ESOPHAGUS CANCER; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; NAUSEA; NEUROBLASTOMA; NEUROTRANSMISSION; NONHUMAN; OVARY CARCINOMA; OVERACTIVE BLADDER; PAIN RECEPTOR; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SLEEP DISORDER; TRANSGENIC MOUSE; TREMOR; URINE INCONTINENCE; URINE RETENTION; UROGENITAL TRACT DISEASE; VOMITING; XEROSTOMIA;

EID: 84882300659     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (218)

1. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ. The biological role of non neuronal acetylcholine in plants and humans. Japanese J Pharmacol 2001; 85: 2-10.
2. + influx into embryonic cells after stimulation of the embryonic muscarinic receptors. J Dev Physiol 1992; 17: 147-155.
3. Buzanikov GA, Shumukler YB, Lauder JM. From oocytes to neuron: do neurotransmitters function in the same way throughout development. Cell Mol Neurobiol 1996; 16: 533-559
4. Grando SA, Pittelkow MR, Schellreunter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical Significance. J Invest Dermatol 2006; 126: 1948-1965.
5. Kawashima K, Fuji T. Expression of non neuronal acetylcholine in lymphocytes and its contributionof immune function. Front Biosci 2004; 9 (suppl):2063-2085.
6. Proskocil BJ, Harmanjatinder SS, Yibing J, Savchenk V, Blakely RD, Lindstrom J, Spindel ER. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology 2004; 145: 2498-2506.
7. Whittacher VP. Identification of acetylcholine and related esters of biological origin. In Eichler O, Farah a., Koelle GB Editors. Handbuch der Experimentellen Pharmakologie. B, Heidelberg, New York Springer 1963; 1-39.
8. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ. The non-neuronal cholinergic system in humans: Expression, function and pathophysiology. Life Sciences 2003; 72: 2055-2061
9. Ma W, Li BS, Zhang L, Pant H. Signalling cascades implicated in muscarinic regulation of proliferation of neural stem and progenitor cells. Drug News Perspect 2004; 17: 258-266
10. Zhou C, Wen ZX, Shi DM, Xie ZP. Muscarinic acetylcholine receptors involved in the regulation of neural stem cell proliferation and differentiation in vitro. Cell Biol Inter 2004; 28: 63-67
11. Augusti TG, Biagioni S, Tata AM. Acetylcholine and regulation of gene expression in developing systems. J Mol Neurosci. 2006; 30: 45-47.
12. Magnaghi V, Procacci P, Tata AM. Novel pharmacological approaches to Schwann cells as neuroprotective agents for peripheral nerve regeneration. Int Rev Neurobiol. 2009; 87: 295-315.
13. Loreti S, Ricordy R, De Stefano ME, Augusti-Tocco G, Tata AM. Acetylcholine inhibits cell cycle progression in rat Schwann cells by activation of M2 receptor subtype. Neuron Glia Biol. 2007; 3: 269-279.
14. De Angelis F, Bernardo A, Magnaghi V, Minghetti L, Tata AM. Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation and differentiation. Dev. Neurobiol. 2012; 72: 713-728.
15. Rosas-Ballina M, Tracey KJ. The neurology of the immune system: neural reflexes regulate immunity. Neuron 2009; 64:28-32.
16. Kawashima K, Fujii T, Extraneuronal cholinergic system in lymphocytes. Pharmacol and Ther 2000; 86: 29-48.
17. Reale M, De Angelis F, Di Nicola M, Capello E, di Ioia M, De Luca G, Lugaresi A, Tata AM. Relation Between ProInflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients. Int. J. Mol. Sci. 2012;13:12656-12664.
18. De Simone R., Ajmone-Cat M, Carnevale D, Minghetti L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2005; 25: 1-10.
19. Levey AI. Immunological localization of m1-m5 muscarinic receptor subtypes in peripheral tissues and brain. Life Sci 1993; 52: 441-448.
20. Ragheb F, Molina-Holgado E, Cui QL, et al. Pharmacological and functional characterization of muscarinic receptor subtypes in developing oligodendrocytes. J Neurochem 2001; 77:1396-1406.
21. Loreti S, Vilarò MT, Visentin S, Rees H, Levey AI, Tata AM. Rat Schwann cells express M1-M4 muscarinic receptor subtypes. J Neurosci Res 2006; 84: 97-105.
22. Caufield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-290.
23. th international symposium on subtypes of muscarinic receptors. Trends Pharmacol Sci 1989; 10 suppl:1-119.
24. Hulme EC, Birsall NJM, Buckley NJ. Muscarinic receptor subtypes. Ann Rev Pharmacol Toxicol 1990; 30:633-673.
25. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ. Distint primary structures, ligand binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 1987; 6: 3923-3929.
26. Caufield MP. Muscarinic receptors: characterization, coupling and function. Pharmacol Ther 1993; 58: 319-379.
27. Taylor P, Brown JH. Acetylcholine. In Basic Neurochemistry. Siegel GJ, Agranoff BW, Albers RW, Molinoff PB. 1994. Raven Press.
28. Tence M, Cordier J, Premont J, Glowinski J. Muscarinic cholinergic agonists stimulate arachidonic acid release from mouse striatal neurons in primary culture. J Pharmacol Exp Ther 1994; 269: 646-653.
29. Conklin BR, Brann MR, Buckley MJM, Bonner IT, Axelrod J. Stimulation of arachidonic acid release and inhibitionof mitogenesis by cloned genes for muscarinic receptor subtypes stably expressed in A9 L cells. Proc Natl Acad Sci USA 1988; 85: 8698-8702.
30. Van Koppen CJ, Kaiser B. Regulation of muscarinic acetylcholine receptor signalling. Pharmacol Ther 2003; 98: 197-220.
31. Cui QL, Fogle E, Almazan G. Muscarinic acetylcholine receptors mediate survival through Src-like tyrosine kinase and PI3K/Akt pathways. Neurochem Int 2006; 48:383-393
32. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nature Rev Drug Discovery 2007; 6:721-733.
33. Stockton JM, Birdsall NJM, Burgen AS, Hulme EC. Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 1983; 44:102-110.
34. Ellis J, Seidenberg M, Brann MR. Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 1993; 42: 199-205.
35. Birdsall NJM, Farries T, Gharagozloo P, et al. Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes. Life Science 1997; 60: 1047-1052.
36. Bolognesi ML, Minarini A, Budriesi R., Cacciaguerra S, Chiarini A., Spampinato S, Tumiatti V, Melchiorre C. Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists. J. Med. Chem. 1998; 41: 4150-4160.
37. Jerulinsky D, Cervenansky C, Pena C, Raskovsky S, Dajas F. Two polypeptides from Dendroaspis angusticeps venom selectivity inhibit the binding of central muscarinic cholinergic receptor ligands. Neurochem Int 1992; 20: 237-246.
38. Max SI, Liang JS, Potter LT. Purification and properties of m1toxin, a specific antagonist of m1 muscarinic receptors. J Neurosci 1993; 13: 4293-4300.
39. Shannon HE, Sheardown MJ, Bymaster FP, et al. Pharmacology of butylthio [2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity. J Pharmacol Exp Ther 1997; 281: 884-894.
40. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, Lindsley CM. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem. 2012; 55: 1445-1464.
41. Conn JP, Lindsley CW, Hopkins CR, Chauder BA, Gogliotti RD, Wood MR: WO2012154731A1 (2012).
42. Felder CC, Bymaster FP, Ward J, Delapp N. Therapeutic opportunities for muscarinic receptors in central nervous system. J Med Chem 2000; 43: 4333-4353.
43. Hedge SS, Mammen M, Jasper JR. Anti-muscarinic for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Inv Drugs 2004; 5:40-49.
44. Eglen RM. Muscarinic receptor subtypes in neuronal and non- neuronal cholinergic function. Autonomic and Autocoid Pharmacol 2005; 26: 219-233
45. Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine: a new muscarinic receptor antagonist, is metabolized by cytochrome P4502D6 and 3A4 in human liver microsomes. Drug Metab Dispos 1998; 26: 289-293.
46. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive blabber syndrome. Expert Opin Pharmacother 2008; 9: 1787-1796.
47. Arth C, Komenda M, Bicane F, Paulus K, Irngartinger M., Lindner H. US 2008/0318421 (2008)
48. Oki T, Maruyama S, Takagi Y, Yamamura HI, Yamada S. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice. Europ J Pharmacol 2006; 529: 157-163.
49. Racke K, Jurgens UR, Matthiesen S. Control by cholinergic mechanisms. Eur J Pharmacol 2006; 533: 57-68.
50. Racke K, Matthiesen S. The airway cholinergic system: physiology and pharmacology. Pulm Pharmacol Ther 2004; 17: 181-198.
51. Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Resp Med 2004; 3: 247-268.
52. Fox RI. Sjogren's syndrome: evolving therapies. Expert Opin Invest Drugs 2003; 12: 247-254.
53. Matsunami H, Li Y.: US20130004983A1 (2013).
54. Eglen RM, Choppin A, Dillon MP, Hegde S. Muscarinic receptor ligands and their therapeutic potential. Curr Op Chem Biol 1999; 3: 426-432.
55. Takeuchi, M., Naito, R., Hayakawa, M., Okamoto, Y., Yonetoku, Y., Ikeda, K., Isomura, Y.: US20006017927 (2000).
56. Meese, C., Sparf, B.: US2004186061 (2004).
57. Cross, P., Mackenzie, A.R.: US5096890 (1992).
58. Dolan, T.F., Humphrey, M.J., Nichols, D.J.: US2006106864 (2000).
59. Karl, Z., Werner, S., Rolf, B., Helmut, W.: US3505337 (1970).
60. Zeile, K., Banholzer, R., Walther, G., Schulz, W., Wick, H.: US3472861 (1969).
61. Box, P.C., Coe, D.M., Looker, B.E., Procopiou, P.A.: US007271197B2 (2007).
62. Box, P.C., Coe, D.M., Looker, B.E., Procopiou, P.A.: US2005256201 (2005).
63. Banholzer, R., Bauer, R., Reichl, R.: US5610163 (1997).
64. Joensson, N.A., Sparf, B.A., Mikiver, L., Moses, P., Nilvebrant, L., Glas, G.: US5382600 (1995).
65. Laine D, Palovich MR, McCleland BW, Neipp CE, Thomas SM.:US8183257 (2012).
66. Laine D, Palovich MR, McCleland BW, Neipp CE, Thomas SM.: EP1740177B1 (2012).
67. Laine D, Palovich MR, McCleland BW, Neipp CE, Thomas SM.: US20120157491A1 (2012).
68. Meese C, Sparf B.: US7,855,230 B2 (2008).
69. Laine D, Palovich MR, McCleland BW, Neipp CE, Thomas SM.: US8309572 (2012).
70. Pfister JR, Rescourio G, Venkatraman MS, Zhang X. US20120029044A1 (2012).
71. Leonardi, A., Motta, G., Riva, C., Testa, R.: US006486163B1 (2001).
72. Kim, Y., Kang S.B., Keum, G., Jang M.S., Kong, J.Y., Jeong, D.Y.: US20030119880A1 (2002).
73. Bymaster, F.P., Horstmann, M., Shannon, H.E., Shipley, L.A., Valia, K.H.: US5980933 (1999).
74. Fisher, A., Karton, I., Heldman, E., Levy, A., Grunfeld, Y.: US4855290 (1989).
75. Hayashi, K., Tokumoto, S., Yoshizawa, H., Isogai, T., Kimura, M., Sawaki, M., Ando, T., Katsuyama, I., Ariyoshi, H., Nakamura, T.: US5571918 (1996).
76. Grewal, G., Toy-Palmer, A., Cai X., Lathman G.M.: US006323194B1 (2000).
77. Shannon HE, Sheardown JM, Bymaster FP et al. Pharmacology of Butylthio [2.2.2](LY297802/NNC11-1053): A novel analgesic with mixed muscarinic receptor agonist and antagonist activity. J Pharmacol Exp Ther 1997; 281: 884-894.
78. Francis P, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzeihmer's disease: a review of progress. J Neurol Neurosurg Pychiatry 1999; 66: 137-14
79. Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer's disease. Proc Natl Acad Sci USA 1996; 93:13541-13546.
80. Bodick NC, Offen WW, Levey AI et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioural symptoms in a Alzheimer disease. Arch Neurol 1997; 54: 465-473.
81. Melancon BJ, Gogliotti RD, Tarr JC, et al. Continued optimization of the MLPCN probe ML071 into higly potent agonist of the M1 muscarinic acetylcholine receptor. Bioorg Med Chem Lett. 2012; 22: 3467-3472.
82. Klose KTJ, Tran NTK, Matthias T, Finnin BC, Reed: US6929801 (2005).
83. Newman AH, Zou MF, Katz JL: US 2008/0226559 (2008).
84. Sur C and Kinney GG. Selective targeting of Muscarinic receptors: novel therapeutic approaches for psychotic disorders. Curr Neuropharmacol 2005; 3:63-71.
85. Sailer M, Oppitz M., Drews U. Induction of cellular contractions in the human melanoma cell line SK-mel 28 after muscarinic cholinergic stimulation. Anat Embryol 2000; 201: 27-37.
86. Oppitz M, Möbus V, Brock S, Drews U. Muscarinic receptors in cell lines from ovarian carcinoma: negative correlation with survival of patients. Gynecologic Oncol 2002; 85: 159-164.
87. Rayford W, Noble MJ, Austenfeld MA, Weigel J, Mebust WK, Shah GV. Muscarinic cholinergic receptors promote growth of human prostate cancer cells. The prostate 1997; 30:160-166.
88. Frucht H, Jensen RT, Dexter D, Yang Wl, Xiao Y. Human colon cancer cell proliferation mediated by the M3 muscarinic cholinergic receptor. Clinical Cancer Res 1999; 5: 2532-2539.
89. Song P, Sekhon HS, Lu A, et al. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogenactivated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res 2007; 67: 3936-3944.
90. Guizzetti M, Costa P, Peters J, Costa LG. Acetylcholine as a mitogen: muscarinic receptor-mediated proliferation of rat astrocytes and human astrocytoma cells. Eur J Pharmacol 1996; 297:265-273.
91. Boss A, Oppitz M, Drews U. Muscarinic cholinergic receptors in the human melanoma cell line SK-MEL28: modulation of chemotaxis. Exp Dermatol 2005; 30: 557-564.
92. Rimmaudo LE, De la Torre E, Sacerdote de Lusting E, Sales ME. Muscarinic receptors are involved in LMM3 tumor cells proliferation and angiogenesis. Biochem Bioph Res Comm 2005; 334: 1359-1364.
93. Jimenez E, Montiel M. Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J Cell Physiol 2005; 204: 678-686.
94. th European meeting on glial cells in health and disease. Medimond Ed. 2009
95. Ferretti M, Fabbiano C, Di Bari M, Ponti D., Calogero A. and Tata AM. M2 muscarinic receptor inhibits cell proliferation in human glioblastoma cell lines. Life Sciences, 2012; 91: 1134-1137.
96. Ferretti M, Fabbiano C, Ricordy R, et al. M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells. J Cell Mol Med. 2013; doi 10.1111/jcmm.12038.
97. Song P, Sekhon HS, Jia Y et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 2003; 63: 214-221.
98. Jimenez E, Montiel M. Activation of MAP kinase by Muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J Cell Physiol 2005; 204: 678-686.
99. Guizzetti M, Wei M, Costa LG. The role of protein kinase C and isozymes in DNA synthesis induced by muscarinic receptors in a glial cell line. Eur J Pharmacol 1998; 359: 223-233.
100. Bordey A, Sontheimer H, Thouslard J. Muscarinic activation of BK channels induces membrane oscillations in glioma cells and leads to inhibition of cell migration. J Membrane Biol. 2000; 176:31-40.
101. WO Patents: 04057344A1 (2004).
102. Arora R, Kadish A, Gilchrist A. US8103151 (2012).
103. Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmakinet 2006; 45: 325-350.
104. Song P. and Spindel ER. Basic and clinic aspect of non neuronal acetylcholine: expression of non neuronal acetylcholine in lung cancer provides a new target for cancer therapy. J. Pharmacol Sci. 2008; 106: 180-185.
105. Nakae K, Nishimura Y, Ohba S, Akamatsu Y. Migrastatin acts as a muscarinic acetylcholine receptor antagonist. J Antibiot 2006; 59: 685-692.
106. Bernardini N, Levey AI, Augusti TG. Rat dorsal root ganglia express m1-m4 muscarinic receptor proteins. J Pheripheral Nervous System 1999; 4: 222-232.
107. Tata AM, Vilaró MT, Mengod G. Muscarinic receptor subtypes expression in rat and chick dorsal root ganglia. Mol Brain Res 2000; 82: 1-10
108. Iwamoto ET, Marion L. Characterization of the antinociception produced by intrathecally administered muscarinic agonistsin rats. J Pharmacol Exp Ther 1993; 266: 329-338.
109. Widman M, Tucker S, Brase DA, Dewey WL. Cholinergic agents: antinociception without morphine type dependence in rats. Life Sci 1985; 36: 2007-2015.
110. Wess J, Duttaroy A, Gomeza J, et al. Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: a review. Life Sciences 2003; 72: 2047-2054
111. Honda K, Harada A, Takano Y, Kamira H. Involvement of M3 muscarinic receptors of the spinal cord in formalin-induced nociception in mice. Brain Res 2000. 859: 38-44.
112. Bernardini N, Sauer S, Haberberger R, Fisher MJM, Reeh PW. Excitatory nicotinic and desensitizing muscarinic (M2) effects on C-nociceptors in isolated rat skin. J Neurosci 2001; 21: 3295-3302.
113. Bernardini N, Roza C, Sauer S, Gomeza J, Wess J, Reeh W. Muscarinic M2 receptors on peripheral nerve endings: a molecular target of antinociception. J Neurosci 2002; 22: 1-5.
114. Dussor GO, Helesic G, Hargreaves KM, Flores CM. Cholinergic modulation of nociceptive responses in vivo and neuropeptide release in vitro at the level of the primary sensory neuron. Pain 2004; 107: 22-32.
115. Ellis JL, Harman D, Gonzalez J et al. Development of muscarinic analgesic derived from epibatidine: role of the M4 receptor subtype. J Pharmacol Exper Ther 1999; 288: 1143-1150.
116. Rubio EA, Hilliard DW. US8071776 (2011).
117. Taylor P, Radic Z. The cholinesterases: From genes to proteins. Annu Rev Pharmacol Toxicol 1994;34:281-320.
118. Karpel R, Ben Aziz-Aloya R, Sternfeld M, et al. Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. Exp Cell Res 1994;210:268-277.
119. Perry C, Sklan EH, Birikh K, et al. Complex regulation of acetyl- cholinesterase gene expression in human brain tumors. Oncogene 2002;21:8428-8441.
120. Genever PG, Birch MA, Brown E, Skerry TM. Osteoblast-derived acetylcholinesterase: A novel mediator of cell-matrix interactions in bone? Bone 1999;24:297-303.
121. Kirkpatrick CJ, Bittinger F, Unger RE, et al. The non-neuronal cholinergic system in the endothelium: Evidence and possible pathobiological significance. Jpn J Pharmacol 2001;85:24-28.
122. Zhang XJ, Yang L, Zhao Q, et al. Induction of acetylcholinesterase expression during apoptosis in various cell types. Cell Death Differ 2002;9:790-800.
123. Day T, Greenfield SA. A non-cholinergic, trophic action of acetyl- cholinesterase on hippocampal neurones in vitro: Molecular mechanisms. Neuroscience 2002;111:649-656.
124. Johnson G, Moore SW. Identification of a structural site on acetyl- cholinesterase that promotes neurite outgrowth and binds laminin-1 and collagen IV. Biochem Biophys Res Commun 2004;319:448-455
125. Soreq H, Patinkin D, Lev-Lehman E, et al. Antisense oligonucleotide inhibition of acetylcholinesterase gene expression induces progenitor cell expansion and suppresses hematopoietic apoptosis ex vivo. Proc Natl Acad Sci 1994;91:7907-7911.
126. Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-891.
127. Reid GA, Chilukuri N, Darvesh S. Butyrylcholinesterase and the cholinergic system. Neuroscience. 2013; doi: 10.1016/j.neuroscience.2012.12.054.
128. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003; 4:131-138.
129. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res. 2003; 28:515-522.
130. Geula C, Nagykery N. Butyrylcholinesterase activity in the rat forebrain and upper brainstem: postnatal development and adult distribution. Exp Neurol. 2007 204:640-57.
131. Millard, C. B. & Broomfield, C. A. A computer model of glycosylated human butyrylcholinesterase. Biochem. Biophys. Res. Commun.; 1992; 189, 1280-1286.
132. R Lockridge, O. et al. Complete amino acid sequence of human serum cholinesterase. J. Biol. Chem. 1987; 262, 549-557.
133. Catalán RE, Martínez AM, Aragonés MD, Hernández F. Molecular forms of butyrylcholinesterase in rat brain microvessels. Neurosci. Letters 1990, 120:46-49.
134. Gauthier S, Lopez OL, Waldemar G, Jones RW, Cummings J, Zhang R, et al. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. Int Psychogeriatr. 2010; 22:973-83.
135. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002; (3):CD001747.
136. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract. 2005; 59:473-7.
137. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006; (1): CD005593.
138. Soreq H, Zakut H. Human Cholinesterases and Anticholinesterases. New York: Academic Press, 1993.
139. Soreq H, Seidman S. Acetylcholinesterase - New roles for an old actor. Nat Rev Neurosci 2001; 2: 294-302.
140. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterase in senile dementia of Alzheimer's type. Neuropathol Applied Neurobiol. 1978; 4: 273-277.
141. Darvesh S, Hopkins D, Geula C Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003; 4: 131-8.
142. Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993; 34: 373-84.
143. Darvesh S, Cash MK, Reid GA, Martin E, Mitnitski A, Geula C. Butirylcholinestarase in associated with -amyloid plaques in the transgenic APPSW/PSEN1dE9 mouse model of Amlzheimer disease. J Neuropathol Exp Neurol. 2012 Jan;71:2-14
144. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in human amygdala and hippocampal formation. J Comp Neurol 1998; 393: 374-390.
145. Darvesh S, Reid GA, Martin E. Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues. Curr Alzheimer Res. 2010; 7:386-400.
146. Eng LF, Uyeda CT, Chao LP, Wolfgram F. Antibody to bovine choline acetyltransferase and immunofluorescent localisation of the enzyme in neurons. Nature 1974; 250: 243-245.
147. Greig NH, Sambamurti K, Yu Q.S., Perry T, Holloway H.W., Haberman F, et al. In: Giacobini E, Eds. Butyrylcholinesterase its Function and Inhibitors. London, Martin Dunitz, 2003: 69-90.
148. Greig N, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. A new therapeutic target in AD treatment: Attention to butyrylcholinesterase: Cur Med. Res Opinions 2001; 17: 1-7.
149. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. International Psychogeriatrics 2002; 14: 77-91.
150. Masson P, Carletti E, Nachon F. Structure, activities and biomedical applications of human butyrylcholinesterase. Protein Pept Lett. 2009; 16: 1215-24.
151. Silman I, Sussman JL. Acetylcholinesterase: how is structure related to function? Chem Biol Interact. 2008; 175: 3-10.
152. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science. 1991; 253: 872-879.
153. Greig NH, Yu QS, Brossi A, Matin E, Lahiri DK, Darvesh S. Butyrylcholinesterase, the Cinderella cholinesterase, as a drug target for Alzheimer's diseases and related dementias. In: Martinez A, Eds. Medicinal Chemistry of Alzheimer's Disease. Kerala, India, Transworld Research Network, Research Signpost, 2008: 79-109.
154. Greig NH, Pei XF, Soncrant TT, Ingram, DK, Brossi A. Phenserine and ring-C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med. Chem. Rev. 1995; 15: 3-31.
155. Saxena A, Redman AM, Jiang X, Lockridge O, Doctor BP. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry. 1997; 36: 14642-51
156. Kitisripanya N, Saparpakorn P, Wolschann P, Hannongbua S. Binding of huperzine A and galanthamine to acetylcholinesterase, based on ONIOM method. Nanomedicine. 2011; 7: 60-68.
157. Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure. 1999; 7: 297-307.
158. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res. 2005; 2 307-318.
159. Yu Q, Holloway HW, Utsuki T, Brossi A, Greig NH. The synthesis of novel phenserine-based-selective inhibitors of butyrylcho- linesterase for Alzheimer's Disease. J Med Chem 1999; 42: 1855-1861.
160. Darvesh S, McDonald RS, Penwell A, Conrad S, Darvesh KV, Mataija D, et al. Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives. Bioorg. Med. Chem. 2005; 13: 211-22
161. Yu QS., Holloway HW, Flippen-Anderson F, Hoffman B, Brossi A, Greig NH. Methyl analogues of the experimental Alzheimer drug, phenserine: synthesis and structure/activity relationships for acetyl- and butyryl-cholinesterase inhibitory action. J Med Chem. 2001; 44: 4062-4072
162. Darvesh S, Darvesh KV, McDonald RS, et al. Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008; 51: 4200-1422.
163. Greig NH, De Micheli E, Utsuki T, Holloway HW, Yu QS, Perry T, et al. The experimental Alzheimer drug phenserine: preclinical pharmacodynamics and kinetics in the rat Acta Neurol Scand 2000; 102: 74-84.
164. Greig NH, Ruckle J, Comer P, Brownell L, Holloway HW, Flanagan DR. Jr., Canfield CJ, et al. Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res. 2005; 2: 482-92.
165. Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma G, Lahiri DK. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res. 2005; 2: 281-91.
166. Klein J. Phenserine. Expert Opin Investig Drugs. 2007; 16: 1087-1097.
167. Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, et al. Phenserine efficacy in Alzheimer's disease. J Alzheimer Dis. 2010; 22: 1201-1208.
168. Kamal MA, Klein P, Yu QS, Tweedie D, Li Y, Holloway HW, Greig NH. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnor-cymserine. J Alzheimer Dis. 2006; 10:43-51.
169. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer -amyloid peptide in rodent. Proc. Natl. Acad. Sci. USA, 2005; 102: 17213-8.
170. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Greig NH, Klein J. Excessive levels of hippocampal acetylcholine in acetyl- cholinesterase-knockout mice are moderated by butyrylcho- linesterase activity. J. Neurochem. 2007; 100: 1421-8.
171. Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J. Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009; 12: 79-85.
172. Cerbai F, Giovannini MG, Melani C, Enz A, Pepeu G. N1-phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. Eur J Pharmacol. 2007; 572: 142-150.
173. Scali C, Giovannini MG, Prosperi C, Bartolini L, Pepeu G. Tacrine administration enhances extracellular acetylcholine in vivo and restores the cognitive impairment in aged rats. Pharmacol Res. 1997; 36: 463-469.
174. Scali C, Giovannini MG, Bartolini L, Prosperi C, Hinz V, Schmidt B, et al. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur J Pharmacol. 1997; 325: 173-180.
175. Cuadra G, Summers K, Giacobini E. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J Pharmacol Exp Ther. 1994; 270: 277-84.
176. Noori HR, Fliegel S, Brand I, Spanagel R. The impact of acetyl- cholinesterase inhibitors on the extracellular acetylcholine concentrations in the adult rat brain: a meta-analysis. Synapse. 2012; 66: 893-901.
177. Adler M, Sweeney RE, Hamilton TA, Lockridge O, Duysen EG, Purcell AL, et al. Role of acetylcholinesterase on the structure and function of cholinergic synapses: insights gained from studies on knockout mice. Cell Mol Neurobiol. 2011; 31: 909-20.
178. Camp S, Zhang L, Krejci E, Dobbertin A, Bernard V, Girard E, et al. Contributions of selective knockout studies to understanding cholinesterase disposition and function. Chem Biol Interact. 2010; 187: 72-77.
179. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol. 2006; 9: 101-24.
180. Wang Y, Greig NH, Yu QS, Mattson MP. Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and sup- presses NMDA currents in hippocampus slices. Neurobiol Aging. 2009; 30: 1061-8.
181. Kapai NA, Bukanova JV, Solntseva EI, Skrebitsky VG. Donepezil in a narrow concentration range augments control and impaired by beta-amyloid peptide hippocampal LTP in NMDAR-independent manner. Cell Mol Neurobiol. 2012; 32: 219-226.
182. Sweatt JD. Toward a Molecular Explanation for Long-Term Potentiation. Learn. Mem. 1999; 6: 399-416.
183. Ingram DK, Spangler EL, Iijima S, Kuo H, Bresnahan EL, Greig NH, et al. New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment. Ann N Y Acad Sci. 1994; 717: 16-32
184. Terry AV Jr, Callahan PM, Hall B, Webster SJ. Alzheimer's disease and age-related memory decline (preclinical). Pharmacol Biochem Behav. 2011; 99: 190-210.
185. Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res. 2009; 6: 86-96
186. Araujo JA, Greig NH, Ingram DK, Sandin J, de Rivera C, Milgram NW. Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. J Alzheimers Dis. 2011; 26: 143-155.
187. Enz A. US5602176 (1997).
188. Davis B. Method of treating Alzheimer's disease: Alzheimer's disease may be treated with galanthamine. US 4663318.
189. Imai A, Hideaki W, Kajima T, Ishihama Y, Ohtsuka A, Tanaka T, Narabu Y. US 5985864. (1997).
190. Bruce F, Vander Zander JJ, Terwillinger RJ, Cheetham JK, Kurian R, Kuan T, Chang CM, Le Espiritu JAM. US7810643 (2010).
191. Asmussen B, Horstmann M, Kopke K, Tiemessen H, Dinh SM, Gargiulo PM. US 6316023 (2001).
192. Martinez A, Castro A. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin Investig Drugs. 2006; 15: 1-12.
193. Kawamata J, Shimohama S. Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis. 2011; 24 Suppl 2: 95-109.
194. Akaike A. Preclinical evidence of neuroprotection by cholinesterase
195. Marcello E, Epis R, Saraceno C, Di Luca M. Synaptic dysfunction in Alzheimer's disease. Adv Exp Med Biol. 2012; 970: 573-601.
196. Daulatzai MA. Early stages of pathogenesis in memory impairment during normal senescence and Alzheimer's disease. J Alzheimers Dis. 2010; 20: 355-67.
197. Perry EK, Johnson M, Kerwin JM, Piggott MA, Court JA, Shaw PJ, et al. Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging. 1992; 13: 393-400.
198. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med. 2002; 1: 1-31.
199. Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, Greig NH. A partial failure of membrane protein turn- over may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res. 2006; 3: 81-90.
200. Chasseigneaux S, Allinquant B. Functions of A, sAPP and sAPP: similarities and differences. J Neurochem. 2012; 120 S1:99-108.
201. Youdim MB. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res. 2006; 3: 541-50.
202. Weinreb O, Amit T, Bar-Am O, Youdim MB. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012; 13: 483-94.
203. Li W, Mak M, Jiang H, Wang Q, Pang Y, Chen K, et al. Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets. Neurotherapeutics. 2009; 6: 187-201.
204. Pi R, Mao X, Chao X, Cheng Z, Liu M, Duan X, et al. Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid- - mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo. PLoS One. 2012; 7(2):e31921.
205. Lahiri DK, Chen D, Maloney B, Holloway HW, Yu QS, Utsuki T, et al. The experimental Alzheimer's disease drug posiphen [(+)- phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther. 2007; 320: 386-396.
206. Haroutunian V, Greig NH, Pei XF, Utsuki T, Gluck R, Acevedo LD, et al. Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res Mol Brain Res. 1997; 46: 161-168.
207. Marutle A, Ohmitsu M, Nilbratt M, Greig NH, Nordberg A, Sugaya K. Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proc Natl Acad Sci U S A. 2007; 104: 12506-12511.
208. Maccecchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig NH. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-peptide and levels: target engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry. 2012; 83: 894-902.
209. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, et al. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci 2001; 98: 7605-7610.
210. Mikkilineni S, Cantuti-Castelvetri I, Cahill CM, Balliedier A, Greig NH, Rogers JT. The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression. Parkinsons Dis. 2012; 2012: 142372.
211. Greig NH, Brossi A, Soncrant T, Holloway HW, Pei X-F, Iijima S, Spangler E, Ingram, DK. Method for treating cognitive disorders with phenserine. a. U.S. 5409948 (1995).
212. Greig NH, Brossi A, Soncrant T, Yu QS, Hausman M. Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias. WO 99/02154, US 6683105 (2004).
213. Greig NH, Shaw KYT, Brossi A, Utsuki T, Yu QS, Holloway HW, Ingram DK, Soncrant TT, Giordano A, Powers G, Sturgess M. US7786162 (2010).
214. Darvesh S, Magee D, Valenta Z, Martin E. Pyridones and their use as modulators of serine hydrolase enzymes. US 6544986 (2003).
215. Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Ann Rev Pharmacol Toxicol 2004; 44:423-450.
216. Mammen, M, Yu-Hua, Ji, Dunham, S, Li, L.: US007151115B2 (2006).
217. Drutu, I, Hurley, DJ, Bandarage UP, Bergeron DJ, Charifson PS, Davies RJ, Blanco GG, Makings LR, Nakatani A, Raffai G.: US 20060270653A1 (2007).
218. De Aquino RAN, Modolo LV, alves RB, de Fatima A. Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure. Curr Drug Targets 2013; 14: 1-20.